GlassScriptPhysician profile
David P Taylor
NPI 1508186990
$6,862.33
in general payments reported to CMS, 2019-2025
27 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $97.80 · 2021: $14.22 · 2022: $5,811 · 2023: $144 · 2024: $310 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.65 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,646.45 | 2022 | |
| Abbvie INC. | $142.09 | 2019-2023 | Liletta |
| Bayer Healthcare Pharmaceuticals INC. | $139.30 | 2019-2025 | |
| Organon LLC | $135.98 | 2023-2025 | Nexplanon |
| Daiichi Sankyo INC. | $120.43 | 2019-2024 | Injectafer |
| Vertex Pharmaceuticals Incorporated | $66.34 | 2024-2025 | |
| Astellas Pharma US INC | $63.07 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $62.70 | 2020 | |
| Sumitomo Pharma America, INC. | $61.84 | 2023-2024 | Myfembree, Gemtesa |
| Merck Sharp & Dohme LLC | $42.26 | 2019-2020 | |
| Coloplast Corp | $40.01 | 2025 | |
| Mylan Pharmaceuticals INC. | $39.77 | 2022 | |
| Mayne Pharma Commercial LLC | $37.87 | 2024 | |
| Evofem Biosciences, INC. | $33.68 | 2023 | Phexxi |
| Medtronic, INC. | $29.17 | 2025 | Truclear |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $28.20 | 2021-2022 | |
| Baxter Healthcare | $20.83 | 2025 | Perclot |
| Meditrina | $18.75 | 2024-2025 | |
| Millicent US INC | $18.67 | 2025 | Intrarosa, Femring |
| Avanos Medical | $17.83 | 2025 | On-Q Pump and Accessories |
| Roche Diagnostics Corporation | $17.78 | 2019 | |
| Mallinckrodt Enterprises LLC | $15.00 | 2019 | |
| Pfizer INC. | $14.59 | 2025 | |
| Sage Therapeutics, LLC | $14.00 | 2024 | |
| Amag Pharmaceuticals, INC. | $13.66 | 2019 | |
| Therapeuticsmd, INC. | $11.11 | 2019 | |
| Vertical Pharmaceuticals, LLC | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.